(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
19 May 2005 (19.05.2005)

PCT

(10) International Publication Number
WO 2005/044816 A1

(51) International Patent Classification[7]: C07D 403/04, 495/04, 491/04, A61K 31/41

(21) International Application Number: PCT/US2004/035927

(22) International Filing Date: 29 October 2004 (29.10.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/516,238 31 October 2003 (31.10.2003) US

(71) Applicants *(for all designated States except US)*: **ARENA PHARMACEUTICALS, INC.** [US/US]; 6166 Nancy Ridge Drive, San Diego, CA 92121 (US). **MERCK & CO., INC.** [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **SEMPLE, Graeme** [GB/US]; 15920 Camino Codorniz, San Diego, CA 92127 (US). **SCHRADER, Thomas** [US/US]; 8526 Villa La Jolla Drive No.147, La Jolla, CA 92037 (US). **SKINNER, Philip, J.** [GB/US]; 1222 Oliver Avenue #2, San Diego, CA 92109 (US). **COLLETTI, Steven, L.** [US/US]; 3 Borosko Place, Princeton Junction, NJ 08550 (US). **GHARBAOUI, Tawfik** [MA/US]; 2340 Lomica Place, Escondido, CA 92029 (US). **IMBRIGLIO, Jason, E.** [US/US]; 280 River Road, Apartment 69B, Piscataway, NJ 08854 (US). **JUNG, Jae-Kyi** [KR/US]; 16478 Camelas Walk, San Diego, CA 92127 (US). **LIANG, Rui** [US/US]; 4 Schindler Court, East Brunswick, NJ 08816 (US). **RAGHAVAN, Subharekha** [US/US]; 900 Perry Lane, Teaneck, NJ 07666 (US). **SCHMIDT, Darby** [US/US]; 25 Dawn Drive, Clark, NJ 07066 (US). **TATA, James, R.** [US/US]; 25 Faulkner Drive, Westfield, NJ 07090 (US).

(74) Agent: **GODDARD, Christine, A.**; Cozen O'Connor, 1900 Market Street, Philadelphia, PA 19103 (US).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: TETRAZOLE DERIVATIVES AND METHODS OF TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF



(I)

(57) Abstract: The present invention relates to certain tetrazole derivatives of Formula (I), and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists for the RUP25 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like. In addition, the present invention also provides for the use of the compounds of the invention in combination with other active agents such as those belonging to the class of α-glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL catabolism enhancers, angiotensin converting enzyme (ACE) inhibitors, insulin secretion enhancers and the like.

WO 2005/044816 A1